R&D News | pharmaphorum

News

Ex-Biogen R&D head Sandrock takes the top job at Voyager

Voyager Therapeutics has lost little time in elevating Al Sandrock to the chief executive position, with the appointment coming just a few weeks after he joined the biotech's board.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

BMS buys into Volastra's cancer expertise with $1.1bn allian...

Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a c

News

Biogen finally publishes its phase 3 Aduhelm data

After months of debate about the validity of its phase 3 clinical trials for Alzheimer's therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to l

News

Longer-term data raise prospects for Apellis' pegcetacoplan

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from

News

Venatorx plans new antibiotic filing after phase 3 readout

Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of

News

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren

Ex-Biogen R&D head Sandrock takes the top job at Voyager

BMS buys into Volastra's cancer expertise with $1.1bn allian...

Biogen finally publishes its phase 3 Aduhelm data

Longer-term data raise prospects for Apellis' pegcetacoplan

Venatorx plans new antibiotic filing after phase 3 readout

AbbVie sees bigger role for Qulipta in migraine prevention

Danco fights back after US court curbs abortion pill access

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks